Despite the advancement of antiretroviral therapy (ART) for the treatment of human
immunodeficiency virus (HIV), drug–drug interactions (DDIs) remain a relevant clinical issue for …

Background: Contemporary first-line antiretrovirals have considerably reduced liability for
clinically significant drug–drug interactions (DDI). This systematic review evaluates the …

Introduction Metabolic inducers can expose people with polypharmacy to adverse health
outcomes. A limited fraction of potential drug–drug interactions (DDIs) have been or can …

The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling
to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (…

Aims Long‐acting cabotegravir and rilpivirine have been approved to manage HIV in adults,
but data regarding safe use in pregnancy are limited. Physiologically‐based …

Tuberculosis remains the leading cause of death among people living with HIV. Rifapentine
is increasingly used to treat active disease or prevent reactivation, in both cases given either …

The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling
to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (…

Objective An in vitro relative activity factor (RAF) technique combined with mechanistic static
modeling was examined to predict drug-drug interaction (DDI) magnitude and analyze …

Background and Objective Induction of drug-metabolizing enzymes can lead to drug-drug
interactions (DDIs); therefore, early assessment is often conducted. Previous reports focused …